PMID: 6165899Apr 1, 1981Paper

Postocclusive cutaneous vasodilatation mediated by substance P

Naunyn-Schmiedeberg's Archives of Pharmacology
F Lembeck, J Donnerer

Abstract

1. The cutaneous vasodilatation following arterial occlusion ("reactive hyperemia") was studied in the rat hind paw. A peak increase in venous outflow of 200-250% was observed within 1 min after a 3 min occlusion period. 2. Chronic denervation as well as capsaicin pretreatment reduced the postocclusive cutaneous vasodilatation by more than 60% (P less than 0.01). This demonstrates that the reactive vasodilatation is of neurogenic origin and mediated by small diameter afferent fibres. 3. Reduction of the postocclusive cutaneous vasodilatation after histamine depletion by compound 48/80 indicates the involvement of histamine. 4. Among all neuropeptides known to occur in primary sensory neurones only substance P and vasoactive intestinal polypeptide cause vasodilatation when infused i.a. into the rat paw. In contrast to antidromic sensory nerve stimulation or i.a. substance P infusion, vasoactive intestinal polypeptide does not cause plasma extravasation. The vasodilator potency of vasoactive intestinal polypeptide is about 1/500 of substance P in the rat paw. Therefore only substance P is able to mimic the reactive vasodilatation. 5. It is concluded that the postocclusive cutaneous vasodilatation is caused mainly by the release o...Continue Reading

References

Jul 1, 1977·The Journal of Investigative Dermatology·G Burnstock
Jan 1, 1978·General Pharmacology·J L Willems, M G Bogaert
Nov 1, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·L A Chahl
Dec 1, 1979·Naunyn-Schmiedeberg's Archives of Pharmacology·F Lembeck, P Holzer
Aug 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·V Chan-Palay, S L Palay
Dec 1, 1977·Acta Physiologica Scandinavica·L OlgartG Nilsson
Dec 1, 1978·Acta Physiologica Scandinavica·J M LundbergS Said
Sep 1, 1978·Microvascular Research·P M Vanhoutte, W J Janssens
Jul 1, 1979·Acta Physiologica Scandinavica·A BillG Nilsson
Oct 15, 1979·European Journal of Pharmacology·P HolzerF Lembeck
Jan 1, 1977·British Journal of Pharmacology·P T ArvierR J Ladd
Jul 1, 1972·Quarterly Journal of Experimental Physiology and Cognate Medical Sciences·J A Kiernan
Apr 1, 1973·Proceedings of the Society for Experimental Biology and Medicine·A R Johnson, E G Erdös
Jun 12, 1974·Naunyn-Schmiedeberg's Archives of Pharmacology·H Juan, F Lembeck
Sep 1, 1967·British Journal of Pharmacology and Chemotherapy·N JancsóJ Szolcsányi
Nov 1, 1980·Naunyn-Schmiedeberg's Archives of Pharmacology·H Juan, W Sametz
Apr 1, 1980·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·V Seybold, R Elde
Apr 1, 1981·Acta Physiologica Scandinavica·E BrodinL Olgart
Mar 1, 1981·Acta Physiologica Scandinavica·S RosellJ Hörig
Jun 1, 1953·The American Journal of Physiology·M J FRUMINS C WANG
Nov 17, 1953·Acta Physiologica Scandinavica·O CELANDER, B FOLKOW
Nov 1, 1957·Journal of Applied Physiology·R R SONNENSCHEIN, M BERNSTEIN
Aug 1, 1961·The Journal of Investigative Dermatology·W B REEDS W BECKER
Aug 27, 1964·Annals of the New York Academy of Sciences·L F CHAPMAN, H GOODELL
May 5, 1964·Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie·K STARKE
Apr 1, 1950·The Journal of Clinical Investigation·I S COOPER

❮ Previous
Next ❯

Citations

Aug 1, 1981·Naunyn-Schmiedeberg's Archives of Pharmacology·F ErjavecP Holzer
Mar 1, 1983·Naunyn-Schmiedeberg's Archives of Pharmacology·G SkofitschF Lembeck
May 1, 1984·Naunyn-Schmiedeberg's Archives of Pharmacology·H JuanF Lembeck
Nov 1, 1985·Naunyn-Schmiedeberg's Archives of Pharmacology·A Franco-Cereceda, J M Lundberg
Apr 1, 1983·Agents and Actions·J Foreman, C Jordan
Jan 28, 1983·European Journal of Pharmacology·J L JorizzoM W Greaves
May 31, 1982·Life Sciences·S H BuckT F Burks
Dec 1, 1984·Brain Research·L C Russell, K J Burchiel
Apr 11, 2003·Neuroscience Letters·Ferenc DomokiGábor Jancsó
May 1, 1992·Acta Anaesthesiologica Scandinavica·G Akerström, B Lisander
Aug 1, 1988·Acta Physiologica Scandinavica·F Lembeck
Nov 1, 1989·Acta Physiologica Scandinavica·A Franco-CerecedaJ M Lundberg
Jan 1, 1996·Journal of Basic and Clinical Physiology and Pharmacology·C Küçükhüseyin, S O Kayaalp
Dec 1, 1991·Journal of Neurosurgery·R MacfarlaneH A Kontos
Mar 1, 1987·Acta paediatrica Scandinavica·G AhlstenT Tuvemo
Dec 31, 1981·Biochemical and Biophysical Research Communications·F LembeckJ Donnerer
Sep 1, 1995·Journal of the American Academy of Dermatology·T LottiE Panconesi
Jan 1, 1989·Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery·M Westin, P Hedén
Apr 5, 2018·Seminars in Immunopathology·João Sousa-Valente, Susan D Brain
Dec 17, 2017·The European Journal of Neuroscience·Tatjana I KichkoPeter W Reeh
Feb 20, 2007·American Journal of Physiology. Heart and Circulatory Physiology·András TóthPaul C Johnson
Feb 1, 1983·Pain·M Fitzgerald
Jan 13, 2004·Journal of Applied Physiology·J L ZhaoD L Kellogg
Aug 1, 1993·Journal of Cellular Biochemistry·T W ReidM J Mannis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.